Global pharma leader Lupin has taken a major step forward in the U.S. biosimilar market with a new exclusive licensing agreement for Armlupeg (pegfilgrastim-unne). The company announced today that it has partnered with Valorum Biologics, a...
AptarGroup, a worldwide leader in dosing, dispensing, and protection technologies for drugs and consumer products, has revealed the purchase of Sommaplast, a Brazil-based company that specializes in oral dosing pharmaceutical packaging solutions
Tata 1mg and OneBanc have forged a strategic partnership aimed at revolutionizing India’s corporate healthcare sector, a market valued at over Rs. 12,000 crore annually across diagnostics, outpatient services, and preventive wellness
.png)
Danish drugmaker Novo Nordisk is preparing to launch Ozempic in India this month, marking a major move in a market already battling rising diabetes and obesity. The arrival of the blockbuster drug comes at a time when India has the world’s...
Agilent Technologies Inc. has launched new 21 CFR Part 11 compliant software for its xCELLigence Real-Time Cell Analysis (RTCA) eSight system
Biocon Biologics is moving fast after securing a major settlement with Amgen that clears the way for its Denosumab biosimilars to enter Europe and global markets. Starting December 2, 2025, the company can commercialize both Vevzuo and Evfraxy...
RPG Life Sciences is stepping into India’s growing GLP-1 market — targeting obesity and diabetes — and laying the groundwork for a bold expansion that could reshape its future. The company has outlined an ambition to reach ?2,500 crore turnover...
The Union health ministry's Drugs Consultative Committee (DCC) has advised the government to modify the Drugs and Cosmetic Rules (D&C Rules) to grant licenses to pharmaceutical marketers under specific conditions aimed at guaranteeing the quality
Cipla Limited has unveiled its first Breathefree Lung Wellness Centre in Lajpat Nagar, New Delhi—marking the debut of India’s first integrated lung diagnostics and wellness facility
Zydus Lifesciences has obtained a provisional license from the U.S. Food and Drug Administration on Empagliflozin and Linagliptin pills. This is a milestone in the U.S. expanding portfolio of the company. It reports about the generic Glyxambi...
, CDSCO.jpg)